EBANGA™ (Ansuvimab-zykl)

About Ridgeback Biotherapeutics

Ridgeback Biotherapeutics is a private, clinical-stage biotech company specializing in antiviral therapeutics for high-need, emerging infectious diseases. Founded and led by healthcare investors Wendy and Wayne Holman, the company has successfully advanced two late-stage assets: the FDA-approved Ebola treatment EBANGA™ and the oral antiviral Lagevrio (molnupiravir) for COVID-19. Ridgeback's strategy centers on identifying and accelerating promising science for pathogens that are often overlooked by larger pharmaceutical players, positioning itself at the intersection of public health response and drug development. The company operates with a lean, virtual model, leveraging partnerships for development and commercialization.

About Vir Biotechnology

Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.

Therapeutic Areas